Clinical Trials

Status
Published

Recently Activated

SHOW MORE

Active Filters

    Open
    Accrual
    0%
    SWOG Clinical Trial Number
    S1823

    A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors

    Status Notes
    The study is open for registration effective 6/1/20.
    Research Committee(s)
    Prevention & Epidemiology
    Genitourinary Cancer
    Activated
    06-01-2020
    Open
    Phase
    III
    Accrual
    0%
    SWOG Clinical Trial Number
    S1914

    A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC

    Status Notes
    This study is open to accrual effective March 25, 2020.
    Research Committee(s)
    Lung Cancer
    Activated
    03-25-2020
    ClinicalTrials.gov Registry Number
    04214262
    Open
    Phase
    II
    Accrual
    2%
    SWOG Clinical Trial Number
    S1900B

    A PHASE II STUDY OF LOXO-292 IN PATIENTS WITH RET FUSION-POSITIVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)

    Status Notes
    S1900B will open to accrual February 10, 2020, effective 12:00 pm PST.

    This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    Lung Cancer
    Activated
    02-10-2020
    Open
    Phase
    SWOG Clinical Trial Number
    CTSU/NRG-GY020

    Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (DMMR) Endometrioid Endometrial Cancer

    Research Committee(s)
    Early Therapeutics & Rare Cancers
    Gynecologic Cancer
    Activated
    02-07-2020
    ClinicalTrials.gov Registry Number
    04214067
    Open
    Accrual
    30%
    SWOG Clinical Trial Number
    S1900C

    A PHASE II STUDY OF TALAZOPARIB PLUS AVELUMAB IN PATIENTS WITH STAGE IV OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER BEARING PATHOGENIC STK11 GENOMIC ALTERATIONS (LUNG-MAP SUB-STUDY)

    Status Notes
    S1900C will open to accrual January 16, 2020, effective 2:00 pm PST.

    This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    Lung Cancer
    Activated
    01-16-2020
    Open
    Phase
    III
    Accrual
    0%
    SWOG Clinical Trial Number
    S1827

    MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

    Status Notes
    This study is open to accrual effective January 10, 2020 at 2:00 p.m. Pacific.
    Research Committee(s)
    Lung Cancer
    Activated
    01-10-2020
    ClinicalTrials.gov Registry Number
    04155034